| Autor: |
Nobuhiro Yamakawa, Masahiro Umeda, Yumi Yoshii, Kenji Mitsudo, Makoto Noguchi, Jingo Kusukawa, Akira Katakura, Hideki Nakayama, Masashi Sasaki, Tadahide Noguchi, Michihiro Ueda, Hiroki Bukawa, Kazuhiro Yagihara, Akihisa Horie, Akihiro Miyazaki, Daichi Chikazu, Kei Tomihara, Katsuaki Mishima, Mitsunobu Otsuru, Seiji Asoda, Shigeyoshi Fujiwara, Yoshio Ohyama, Hiroshi Kurita, Hitoshi Kawamata, Masayuki Fukuda, Yukari Shintani, Takanori Kobayashi, Takahiro Kanno, Ichiro Oh‐iwa, Kenji Kawano, Yoshio Yamashita, Wataru Kobayashi, Yoichi Ohiro, Katsuhiro Uzawa, Yoshihide Ota, Tadaaki Kirita |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Oral diseases. |
| ISSN: |
1601-0825 |
| Popis: |
Immunotherapy with nivolumab for patients with recurrent/metastatic oral squamous cell carcinoma has not been evaluated. Here, we aimed to examine the efficacy, safety, and prognostic factors of nivolumab in these patients.This multicentre retrospective observational study involved patients who received nivolumab between April 2017 and June 2019. The patient characteristics were evaluated for association with progression-free and overall survival. Progression-free and overall survival rates were calculated; parameters that were significant in the univariate analysis were used as explanatory variables. Independent factors for progression-free and overall survival were identified using multivariate analysis.Totally, 143 patients were included. The overall response and disease control rates were 27.3% and 46.2%, respectively. The median, 1-year, and 2-year progression-free survival rates were 2.7 months, 25.4%, and 19.2%, respectively; those for overall survival were 11.2 months, 47.3%, and 33.6%, respectively. The independent factors affecting progression-free survival were performance status and immune-related adverse event occurrence, whereas those affecting overall survival were performance status, target disease, and number of previous lines of systemic cancer therapy. Eight patients reported grade ≥3 immune-related adverse events.Nivolumab was effective for recurrent/metastatic oral squamous cell carcinoma treatment and was well tolerated by patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text